FDA-cleared in November 2025, the Francis Medical Vanquish Water Ablation System is a transurethral, ultrasound and electromagnetically guided, thermal water vapor device used to convectively ablate targeted prostate tissue. One in eight men will be diagnosed with prostate cancer in their lifetime. The majority of men with localized, low-to-intermediate risk prostate cancer will be presented with one of two options: whole prostate gland removal or radiation, which have a high potential for long-term side effects, or active surveillance, which allows them to maintain their quality of life. The Vanquish System offers a less invasive alternative for men looking for options that can help reduce the potential impact to their quality of life. The outpatient procedure harnesses the energy stored in water vapor (steam) to transfer energy to targeted tissue anywhere in the prostate, causing cell death. Vapor respects the natural boundaries of the prostate, minimizing or eliminating the potential for damage to structures outside the prostate. The Vanquish System includes capital, disposables and an informative user interface that displays recorded MRI images with real-time ultrasound and cystoscopy to support targeted ablation of prostate tissue.
